{"anticipatedPostingDate":"2011-06","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"Number of patients alive and without disease at 1 year after transplant.","groups":[{"description":"Includes patients with partial matched unrelated donor transplants and treated with: total body irradiation twice daily on days -10 and -9 and receive thiotepa intravenously (IV) over 4 hours on days -8 and -7, fludarabine phosphate IV over 30-60 minutes on days -7 to -3, and antithymocyte globulin IV over 4-6 hours on days -5 to -2.\n\nPatients undergo filgrastim (G-CSF)-mobilized, T-cell-depleted, CD34+-selected allogeneic PBSC transplantation on day 0.","id":"OG000","title":"All Treated Patients"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 Year","title":"Incidence of Disease-free Survival","type":"PRIMARY","unitOfMeasure":"Participants"}